News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
623,550 Results
Type
Article (37638)
Company Profile (117)
Press Release (585795)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (172934)
Career Advice (2759)
Deals (32431)
Drug Delivery (91)
Drug Development (72862)
Employer Resources (158)
FDA (15664)
Job Trends (14621)
News (300848)
Policy (29155)
Tag
Academia (2674)
Academic (1)
Accelerated approval (4)
Adcomms (24)
Allergies (92)
Alliances (43448)
ALS (100)
Alzheimer's disease (1424)
Antibody-drug conjugate (ADC) (127)
Approvals (15673)
Artificial intelligence (266)
Autoimmune disease (27)
Automation (17)
Bankruptcy (289)
Best Places to Work (12122)
BIOSECURE Act (17)
Biosimilars (100)
Biotechnology (83)
Bladder cancer (80)
Brain cancer (26)
Breast cancer (303)
Cancer (2325)
Cardiovascular disease (181)
Career advice (2291)
Career pathing (32)
CAR-T (158)
Cell therapy (452)
Cervical cancer (19)
Clinical research (59621)
Collaboration (867)
Company closure (1)
Compensation (575)
Complete response letters (20)
COVID-19 (2540)
CRISPR (45)
C-suite (265)
Cystic fibrosis (106)
Data (2371)
Decentralized trials (1)
Denatured (9)
Depression (42)
Diabetes (268)
Diagnostics (6632)
Digital health (18)
Diversity (3)
Diversity, equity & inclusion (38)
Drug discovery (116)
Drug pricing (103)
Drug shortages (19)
Duchenne muscular dystrophy (96)
Earnings (68791)
Editorial (42)
Employer branding (21)
Employer resources (138)
Events (102773)
Executive appointments (778)
FDA (17059)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (777)
Gene editing (115)
Generative AI (20)
Gene therapy (329)
GLP-1 (645)
Government (4119)
Grass and pollen (5)
Guidances (157)
Healthcare (19867)
Huntington's disease (22)
IgA nephropathy (27)
Immunology and inflammation (116)
Indications (30)
Infectious disease (2687)
Inflammatory bowel disease (148)
Inflation Reduction Act (9)
Influenza (54)
Intellectual property (103)
Interviews (543)
IPO (16194)
IRA (41)
Job creations (2932)
Job search strategy (1899)
Kidney cancer (11)
Labor market (32)
Layoffs (443)
Leadership (23)
Legal (6468)
Liver cancer (72)
Lung cancer (319)
Lymphoma (148)
Machine learning (9)
Management (59)
Manufacturing (324)
MASH (78)
Medical device (14012)
Medtech (14017)
Mergers & acquisitions (16910)
Metabolic disorders (647)
Multiple sclerosis (80)
NASH (13)
Neurodegenerative disease (103)
Neuropsychiatric disorders (24)
Neuroscience (1990)
NextGen: Class of 2025 (6721)
Non-profit (4828)
Now hiring (30)
Obesity (313)
Opinion (234)
Ovarian cancer (82)
Pain (102)
Pancreatic cancer (85)
Parkinson's disease (163)
Partnered (20)
Patents (250)
Patient recruitment (118)
Peanut (49)
People (51864)
Pharmaceutical (35)
Pharmacy benefit managers (19)
Phase I (18559)
Phase II (26431)
Phase III (19812)
Pipeline (1381)
Policy (140)
Postmarket research (2058)
Preclinical (7612)
Press Release (62)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (259)
Rare diseases (399)
Real estate (4924)
Recruiting (63)
Regulatory (20674)
Reports (27)
Research institute (2449)
Resumes & cover letters (449)
Rett syndrome (6)
RNA editing (4)
RSV (45)
Schizophrenia (74)
Series A (127)
Series B (92)
Service/supplier (6)
Sickle cell disease (58)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (25)
Startups (3050)
State (2)
Stomach cancer (10)
Supply chain (66)
Tariffs (48)
The Weekly (38)
Vaccines (663)
Venture capitalists (34)
Weight loss (185)
Women's health (26)
Worklife (18)
Date
Today (117)
Last 7 days (995)
Last 30 days (3326)
Last 365 days (33227)
2025 (12365)
2024 (36057)
2023 (41365)
2022 (52232)
2021 (57141)
2020 (55643)
2019 (48775)
2018 (36683)
2017 (32197)
2016 (30464)
2015 (35549)
2014 (24805)
2013 (19331)
2012 (20850)
2011 (21634)
2010 (18715)
Location
Africa (768)
Alabama (59)
Alaska (7)
Arizona (159)
Arkansas (12)
Asia (36397)
Australia (6481)
California (6512)
Canada (2083)
China (549)
Colorado (281)
Connecticut (297)
Delaware (163)
Europe (84629)
Florida (976)
Georgia (228)
Idaho (58)
Illinois (562)
India (23)
Indiana (330)
Iowa (10)
Japan (171)
Kansas (104)
Kentucky (27)
Louisiana (11)
Maine (71)
Maryland (921)
Massachusetts (4968)
Michigan (248)
Minnesota (410)
Mississippi (2)
Missouri (90)
Montana (31)
Nebraska (25)
Nevada (69)
New Hampshire (69)
New Jersey (1838)
New Mexico (30)
New York (1838)
North Carolina (1057)
North Dakota (9)
Northern California (2889)
Ohio (219)
Oklahoma (14)
Oregon (35)
Pennsylvania (1449)
Puerto Rico (13)
Rhode Island (34)
South America (1093)
South Carolina (26)
South Dakota (1)
Southern California (2473)
Tennessee (108)
Texas (960)
United States (24635)
Utah (199)
Virginia (159)
Washington D.C. (63)
Washington State (584)
West Virginia (3)
Wisconsin (62)
623,550 Results for "astrazeneca ab".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pipeline
AstraZeneca Abandons Neuroscience, Prioritizes Weight Loss, Immunology
Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro altogether.
April 29, 2025
·
3 min read
·
Tristan Manalac
China
AstraZeneca Makes Potential $10B+ China Commitment Despite Political Pressure
The investments come amid an ongoing insurance fraud probe into AstraZeneca’s former China head Leon Wang—and despite mounting pressure from President Trump for pharma companies to re-shore their manufacturing operations.
March 24, 2025
·
2 min read
·
Tristan Manalac
Stomach cancer
AstraZeneca Builds Stomach Cancer Case for Imfinzi With Strong Phase III Data
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The PD-L1 blocker brought in over $4.7 billion in sales last year.
March 7, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
AstraZeneca Makes Potential $1B Cell Therapy Play in EsoBiotec Buy
AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and Gracell Biotechnologies.
March 17, 2025
·
2 min read
·
Tristan Manalac
Earnings
AstraZeneca Axes Two Alexion Assets as Q4 Earnings Exceed Expectations
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” deal for the pharma.
February 6, 2025
·
3 min read
·
Tristan Manalac
Collaboration
AstraZeneca Sets Sights and $1.35B on Subcutaneous Cancer Drugs With Alteogen Alliance
Monday was a busy day for AstraZeneca, which also paid up to $1 billion to acquire Belgian biotech EsoBiotec and its cell therapy pipeline and technology.
March 18, 2025
·
2 min read
·
Tristan Manalac
Podcast
AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More
A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an investigation into China exec, the Huntington’s pipeline builds momentum and layoffs continue with Sana Biotechnology and 23andMe.
November 13, 2024
·
1 min read
·
Heather McKenzie
Cancer
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments in terms of progression-free survival, according to AstraZeneca.
February 26, 2025
·
1 min read
·
Dan Samorodnitsky
Mergers & acquisitions
AstraZeneca Buys FibroGen’s China Unit for $160M as Probes Continue
A year ago, AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to retain its relationship with the biotech’s China operations.
February 20, 2025
·
2 min read
·
Tristan Manalac
Prostate cancer
AstraZeneca’s Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails
The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17%.
April 30, 2025
·
2 min read
·
Tristan Manalac
1 of 62,355
Next
